Bohle Fluid Bed System
The Bohle Fluid Bed System offers numerous advantages and various options in the pharmaceutical production without alteration of equipment setup. Through the tangential-spray technology, this processing design is much more robust than traditional Wurster technology.
Bohle Fluid Bed System
The optimized granulation and drying system Bohle Fluid Bed System BFS, from the smallest system BFS 3 to the largest BFS 480, offers numerous advantages and various options in the pharmaceutical production without alteration of equipment setup. Thanks to the tangential spray system, the Bohle Fluid Bed System 240 is a highly efficient machine. In addition to highly efficient drying, the system is equipped with eight tangential spray nozzles and is suitable for granulation and pellet-coating. This decisive advantage eliminates the need of retrofitting the system when changing from granulation to coating. Through the tangential-spray technology, this new processing design is much more robust than traditional Wurster technology. Moreover, fewer components optimized this system:
- The Bohle Uni Cone BUC ® distributor plate
- Complete particle fluidization due to equipment geometry enables
- High coating uniformity
- High yields due to absence of partical twinning
- Short changeover times due to short transfer and cleaning cycles
- Easy scale up due to geometric similarity
- Economical: small footprint
- Safe: 12 bar pressure shock resistant
- PAT integration possible
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
